Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026

Perspective Therapeutics, Inc. (NYSE: CATX) announced that data from its lapemelanotide zapixetar program, also known as [212Pb]VMT01, has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, scheduled for November 4 to 8, 2026, in Phoenix, Arizona. Further details regarding the regular abstracts will be released by SITC on November 3, 2026.